New biosimilar aims to match pertuzumab in breast cancer fight

NCT ID NCT04514419

Ongoing Disease control Sponsor: BioRay Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a new drug called HS627 (a biosimilar) works as well as pertuzumab when given with trastuzumab and docetaxel before surgery for HER2-positive breast cancer. About 408 people with early-stage or locally advanced breast cancer took part. The main goal is to see if the cancer completely disappears in the breast tissue after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS627 (a biosimilar to pertuzumab)
What this could lead to: If it works, this could offer a more affordable or equally effective alternative to pertuzumab for treating HER2-positive breast cancer before surgery.
What could go wrong: This is a phase 3 trial, but it's comparing a biosimilar to an established drug. The biosimilar may not prove as effective or safe, and results may not apply to all breast cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.